Literature DB >> 16990571

High von Willebrand factor levels increase the risk of first ischemic stroke: influence of ADAMTS13, inflammation, and genetic variability.

Tamara N Bongers1, Moniek P M de Maat, Mary-Lou P J van Goor, Vinod Bhagwanbali, Huub H D M van Vliet, Encarna B Gómez García, Diederik W J Dippel, Frank W G Leebeek.   

Abstract

BACKGROUND AND
PURPOSE: Elevated von Willebrand factor (vWF) concentrations are associated with an increased risk of ischemic heart disease. Several factors influence vWF antigen levels and activity, including blood group, genetic variability, acute-phase response, and proteolysis by A Disintegrin and Metalloprotease with ThromboSpondin motif (ADAMTS13), a determinant of proteolytic cleavage of vWF. We assessed how these factors affect the relation between vWF and the occurrence of stroke to understand the underlying mechanism.
METHODS: In a case-control study of 124 first-ever ischemic stroke patients and 125 age- and sex-matched controls, we studied vWF antigen (vWF:Ag), vWF ristocetin cofactor activity (vWF:RCo), ADAMTS13 activity, the -1793C/G polymorphism in the vWF gene, and C-reactive protein.
RESULTS: vWF antigen and activity levels were significantly higher in cases than in controls. The relative risk of ischemic stroke was highest in individuals in the upper quartile of vWF:Ag (odds ratio, 3.2; 95% CI, 1.4 to 7.5) and vWF:RCo (odds ratio, 2.1; 95% CI, 0.9 to 4.8) compared with individuals in the lowest quartiles. In individuals with ADAMTS13 in the lowest quartile, the relative risk of stroke was 1.7 (95% CI, 0.7 to 3.9) compared with the highest quartile. C-reactive protein, ADAMTS13, and genetic variation did not affect the association between vWF and the relative risk of stroke, whereas blood group did affect the association.
CONCLUSIONS: vWF antigen and activity are associated with the occurrence of acute ischemic stroke. This relation is unaffected by the severity of the acute-phase response or by genetic variation or degradation.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16990571     DOI: 10.1161/01.STR.0000244767.39962.f7

Source DB:  PubMed          Journal:  Stroke        ISSN: 0039-2499            Impact factor:   7.914


  69 in total

1.  Von Willebrand Factor: Multimeric Structure and Functional Activity in Patients With Atrial Fibrillation With and Without Oral Anticoagulation.

Authors:  Sandra Lopez-Castaneda; Ignacio Valencia-Hernández; Carlos Arean; Daniel Godínez-Hernández; Martha Eva Viveros-Sandoval
Journal:  Clin Appl Thromb Hemost       Date:  2017-06-15       Impact factor: 2.389

Review 2.  Laboratory testing for von Willebrand disease: toward a mechanism-based classification.

Authors:  Richard Torres; Yuri Fedoriw
Journal:  Clin Lab Med       Date:  2009-06       Impact factor: 1.935

Review 3.  From structure to redox: The diverse functional roles of disulfides and implications in disease.

Authors:  Tyler J Bechtel; Eranthie Weerapana
Journal:  Proteomics       Date:  2017-03       Impact factor: 3.984

4.  ADAMTS13 and von Willebrand factor interactions.

Authors:  Catherine B Zander; Wenjing Cao; X Long Zheng
Journal:  Curr Opin Hematol       Date:  2015-09       Impact factor: 3.284

Review 5.  Structure-function and regulation of ADAMTS-13 protease.

Authors:  X L Zheng
Journal:  J Thromb Haemost       Date:  2013-06       Impact factor: 5.824

6.  Longitudinal assessment of von Willebrand factor antigen and von Willebrand factor propeptide in response to alteration of antiplatelet therapy after TIA or ischaemic stroke.

Authors:  W O Tobin; J A Kinsella; G F Kavanagh; J S O'Donnell; R T McGrath; T Coughlan; D R Collins; D O'Neill; B Egan; S Tierney; T M Feeley; R P Murphy; D J H McCabe
Journal:  J Neurol       Date:  2014-04-30       Impact factor: 4.849

7.  The changes of von willebrand factor/a disintegrin-like and metalloprotease with thrombospondin type I repeats-13 balance in aneurysmal subarachnoid hemorrhage.

Authors:  Qi-Feng Tang; Shi-Qi Lu; Yi-Ming Zhao; Jin-Xian Qian
Journal:  Int J Clin Exp Med       Date:  2015-01-15

8.  ABO blood type and stroke risk: the REasons for Geographic And Racial Differences in Stroke Study.

Authors:  N A Zakai; S E Judd; K Alexander; L A McClure; B M Kissela; G Howard; M Cushman
Journal:  J Thromb Haemost       Date:  2014-04       Impact factor: 5.824

9.  Interaction between vWF levels and aspirin resistance in ischemic stroke patients.

Authors:  Yıldız Arslan; Tahir Kurtuluş Yoldaş; Yaşar Zorlu
Journal:  Transl Stroke Res       Date:  2013-04-25       Impact factor: 6.829

10.  Role of reduced ADAMTS13 in arterial ischemic stroke: a pediatric cohort study.

Authors:  Moritz Lambers; Neil A Goldenberg; Gili Kenet; Fenella J Kirkham; Daniela Manner; Timothy Bernard; Rolf M Mesters; Ralf Junker; Monika Stoll; Ulrike Nowak-Göttl
Journal:  Ann Neurol       Date:  2012-12-07       Impact factor: 10.422

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.